Organigram Global Inc.

OGI

$1.17

-1.68%

N/A-$0.02

Healthcare

Drug Manufacturers - Specialty & Generic

NASDAQ

Active Trading

Organigram Global Inc., primarily operating through its subsidiary Organigram Holdings Inc., is a Canadian enterprise specializing in the cultivation, production, and distribution ...

Fundamental Analysis of OGI

Key Strengths

Established Canadian operator with an indoor-production model serving both medical and adult-use demand

Strong reported liquidity (current ratio ~2.61; quick ratio ~1.07) and comparatively low leverage (debt-to-equity ~0.065)

Risk Factors

Sustained profitability pressure: negative gross margin (~-5.7%), negative operating margin (~-37.3%), and negative EBITDA margin (~-14.6%)

Weak cash generation: negative free cash flow and poor operating cash flow coverage metrics

Profitability

Net Margin28.02%

Operating Margin-37.35%

Valuation

P/E Ratio2.46x

Current Ratio2.61

Efficiency

ROE21.99%

ROA10.56%

Fundamental Analysis of OGI

Organigram Global Inc. (NASDAQ: OGI) is a Canadian cannabis producer and wholesaler, active in both medical and adult-use markets, with additional international presence (notably Germany via Sanity Group referenced in public materials). The fundamental picture for OGI is mixed to weak: valuation appears modest by some accounting multiples, but profitability quality and cash generation look challenged. On TTM profitability metrics, the company shows negative operating fundamentals with operating profit margin at about -37.3% and EBITDA margin around -14.6%. Gross margin is also negative (about -5.7%), which signals either pricing pressure, cost inefficiencies, or inventory/production-related headwinds rather than a stable, scalable cost position. Balance-sheet liquidity appears supported by reported working capital (~$172.8M) and a relatively healthy current ratio (2.611) and a quick ratio near 1.072. Leverage looks limited based on debt ratios (debt-to-equity ~0.065), which is a potential positive: the firm is not heavily leveraged versus equity. However, several cash flow and coverage metrics raise concern. Free cash flow is negative (free cash flow yield TTM is about -0.125 and free cash flow to firm/equity are negative), and operating cash flow ratios are also weak (operating cash flow ratio and coverage measures are negative). Interest coverage is reported as extremely negative (interest coverage ratio ~ -213), indicating that earnings/cash flow are not comfortably covering interest costs under the current trailing-period profile. Valuation is complicated by the mix of metrics: the stock trades at low P/E (around 2.66) and low price-to-book (~0.48), but that often reflects depressed earnings and uncertainty rather than true value creation. Return metrics are inconsistent: return on equity (about 22%) and ROA (about 10.6% per TTM) appear elevated, yet operating return on assets and invested-capital returns are negative, and margin metrics remain loss-making—suggesting accounting effects, non-operating gains, or volatility in earnings components. Overall, for long-term investors, OGI’s thesis depends on sustained cost improvements, stable legalization/market demand, and improved cash generation; without that, the risk/reward skews toward “speculative hold.”

Key Strengths of OGI

Established Canadian operator with an indoor-production model serving both medical and adult-use demand
Strong reported liquidity (current ratio ~2.61; quick ratio ~1.07) and comparatively low leverage (debt-to-equity ~0.065)
Diversified channel exposure (medical, wholesale, online and adult-use retail/wholesale networks)
International footprint referenced via Germany (Sanity Group) which can help diversify revenue streams
Brand and product portfolio breadth in dried flower, oils/concentrates, edibles, and pre-roll formats

Risk Factors of OGI

Sustained profitability pressure: negative gross margin (~-5.7%), negative operating margin (~-37.3%), and negative EBITDA margin (~-14.6%)
Weak cash generation: negative free cash flow and poor operating cash flow coverage metrics
High operational/cycle inefficiency risk indicated by a long operating cycle (~289 days) and cash conversion cycle (~177 days)
Earnings quality concerns implied by margin inconsistencies (e.g., pretax/continuous operations profitability vs negative operating/EBIT/EBITDA margins) and negative income-quality metric
Industry structural risks: pricing pressure, regulatory changes, and competition in legalized cannabis markets
Sensitivity to macro and policy shifts (taxation, tariffs/trade disputes, and changes in legalization enforcement across regions)

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$164.71M

2.5x

P/E Ratio

0.7x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin-5.67%

Net Profit Margin28.02%

Debt/Equity Ratio0.06

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of OGI

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of OGI

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	99.77%	—	—	Flat
Operating Margin	—	5.04%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of OGI

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	2.611	—	—	Flat
Quick Ratio	—	1.072	—	—	Flat
Debt / Equity	—	0.038	—	—	Flat

Valuation of OGI

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	0.47x	—	—	Flat
P/B	—	0.36x	—	—	Flat

Supply Chain of OGI

RELATIONS

Upstream

Phylos Bioscience Inc.Packaging & Cultivation Supplies Vendors (Various)

Downstream

Ontario Cannabis Store (OCS)Alberta Gaming, Liquor and Cannabis (AGLC)Société Québécoise du Cannabis (SQDC)BC Liquor Distribution Branch (BCLDB)Canopy Growth CorporationNASDAQ:CGC InterCure Ltd. (dba Canndoc)NASDAQ:INCRAvida MedicalLeafio (wholesale arm of Montu Australia / Montu Group Pty Ltd)Sanity Group GmbHProvincial Distributors (Other Canadian Provinces)

Proxies

Tilray Brands Inc.NASDAQ:TLRY Cronos Group Inc.NASDAQ:CRON Aurora Cannabis Inc.NASDAQ:ACB Canopy Growth CorporationNASDAQ:CGC

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer